Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
DUBLIN, Ireland, Oct. 19, 2016 -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapy developer, today announced that its Chief Executive Officer, Dr. Mark Heffernan, is scheduled to present at the 25th Annual Credit Suisse Healthcare Conference in Scottsdale, AZ on Monday, November 7th at 11:00AM MT.
Dr. Heffernan will provide an overview of Nexvet’s pivotal-stage clinical programs for chronic pain in cats and dogs, as well as its therapies in development in the areas of immuno-oncology, inflammation, and allergy.
The presentation will be available on the investor section of Nexvet's website at http://ir.nexvet.com following the completion of the event.
About Nexvet (www.nexvet.com)
Nexvet is a veterinary biologic therapeutics company focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet’s proprietary PETization™ platform is designed to rapidly design monoclonal antibodies (mAbs) that are recognized as “self” or “native” by an animal’s immune system, a property Nexvet refers to as “100% species-specificity.” Nexvet’s product candidates build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.
Nexvet is leveraging diverse global expertise and incentives to build a vertically integrated biopharmaceutical company, which conducts drug discovery in Australia, conducts clinical development in the United States and Europe and conducts biomanufacturing in Ireland.
Further information:
Investors
Candice Knoll
Blueprint Life Science Group
+1 415-375-3340 Ext. 4
[email protected]
Media
Jessica Burns
Berry & Company Public Relations
+1 212-253-8881
[email protected]
